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Abstract The intracellular expression of recombinant antibod-
ies in mammalian cells is an experimental strategy to inhibit in 
vivo the function of selected molecules. However, one limitation 
of this technology is represented by the unpredictable behaviour 
of antibodies, under conditions of intracellular expression. For 
this reason, it would be desirable to exploit intracellular 
expression of antibodies to select or rescue more efficient ones 
from a polyclonal mixture. In this work we have successfully 
explored this possibility by rescuing a neutralizing anti-viral 
antibody fragment from an intracellularly expressed anti-reverse 
transcriptase polyclonal repertoire. 
© 1997 Federation of European Biochemical Societies. 
Key words: Recombinant antibody; Anti-HIV antibody; 
Polyclonal repertoire; Mammalian cell 
1. Introduction 
The intracellular expression of recombinant antibodies tar-
geted to different intracellular compartments [1,2] is an exper-
imental strategy to interfere with the function of selected mol-
ecules. In recent years, this technology has been increasingly 
utilized in a variety of different systems [3,4], for research and 
biomedical purposes. Most of the antibodies utilized so far for 
intracellular immunization have been derived from hybrido-
mas of predefined specificity, after cloning of the correspond-
ing genes and their engineering into more suitable formats, 
such as, for instance, single chain antibody fragments 
(ScFv). However, the efficacy of an intracellularly targeted 
antibody fragment does not always correlate with the proper-
ties of the parental monoclonal antibody, as determined in 
vitro (reviewed in [5]). This is because the intrinsic overall 
stability and solubility of antibodies is contributed by many 
critical residues or combination of residues in the framework 
regions [6,7], and this may differently affect their folding and 
half-life when ectopically expressed in the reducing conditions 
of the cell cytoplasm. Moreover, inhibition in vivo has also 
been observed by antibodies that are non-neutralizing in vitro 
[8]. Finally, for many protein antigens an in vitro neutraliza-
tion assay is not always available and an active epitope is not 
known a priori, making the choice of the monoclonal to be 
intracellularly expressed difficult. For all these reasons, it 
would be desirable to exploit intracellular expression of anti-
bodies to select or rescue more efficient ones from a polyclo-
nal mixture. While the monoclonal antibody technology does 
not easily allow to handle recombinant versions of polyclo-
nals, new antibody technologies seem more suitable in this 
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respect. Antibodies are increasingly being derived from phage 
display libraries [9]. Among the advantages of this technology 
is the fact that the antibodies, most frequently ScFv frag-
ments, are coselected on antigen columns together with their 
corresponding genes. Therefore a polyclonal population of 
antigen binding phage also provides the genes for the corre-
sponding affinity purified polyclonal antibodies. 
We have recently provided the first example that phage 
derived antibody fragments can be successfully used for intra-
cellular immunization [10]. We showed that an antibody frag-
ment derived from a large phage display library, directed 
against the reverse transcriptase of human immunodeficiency 
virus (HIV-1 RT), can inhibit viral retrotranscription, upon 
intracellular expression as a cytosolic protein. In this paper we 
explore the possibility of rescuing an anti-viral neutralizing 
antibody, from an intracellularly expressed polyclonal reper-
toire, by imposing a selective pressure of a cytotoxic retrovi-
rus. This would allow to extend the intracellular expression of 
single antibody specificities, to that of more diverse reper-
toires. 
2. Materials and methods 
2.1. Selection and screening of anti-HIV-1 RT phage antibody 
fragments 
Recombinant HIV-1 RT [11] was used to select single chain Fv 
fragments (ScFv) from phage display libraries of human Fab [12] 
and ScFv fragments [13]. The selection from the Fab library was 
previously described [11]. The selection from the ScFv library was 
performed as described [13], through three cycles of phage growth 
and selection with HIV-1 RT coated on immunotubes (Nunc), at a 
concentration of 10 μg/ml in phosphate buffered saline (PBS). Phage-
ELISA on solid phase HIV-1 RT (10 μg/ml in PBS) was performed as 
described [12], using either a sheep anti-fd antisera (for the Fab li-
brary) or an anti-M13 antisera (for the ScFv library), followed by a 
peroxidase conjugated secondary antibody. The RT RNA-dependent 
DNA-polymerase activity was measured by mixing 250 ng/ml re-
combinant HIV-1 RT and 5X 10n phage particles/ml in reaction buff-
er (PBS, 2.5 mM MgCl2, 1.5 mM [a-32P]dGTP, 10 μ^piιΐ poly-rC/ 
oligo-dG), in a total volume of 20 μΐ. After preincubation of RT and 
phages for 20 min on ice, the reaction was started at 37°C and termi-
nated after 30 min by adding 1 ml of ice cold PBS. The mix was then 
filtered on DE81 Chromatographie paper, followed by washing of the 
filters three times with 5% Na2HP04 and once with water. Radio-
activity bound to the filters was finally counted. 
2.2. Plasmids, cell cultures and viral challenge 
For the expression of antibody fragments in mammalian cells, plas-
mids pScFvexp-D7aRT and pScFvexp-polyaRT were constructed by 
subcloning Ncol-Notl fragments from pUC119-FabD7 [11] and 
pCANTAB-6-polyoeRT (third round of selection) [13] respectively, 
into Ncol-Notl cut pScFvexp. These vectors direct the expression of 
cytosolic antibody fragments under the transcriptional control of the 
EF-BOS (elongation factor-la) promoter [14]. Murine fibroblast Balb/ 
C-3T3 cells were cultured in DMEM medium supplemented with 10% 
fetal calf serum (FCS). Transfection of Balb/c-3T3 cells with 
pScFvexp-D7aRT and pScFvexp-polyaRT vectors was performed 
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by electroporation: cells were trypsin harvested, washed twice with 
PBS and resuspended in 0.3 ml of DMEM medium (1.3 X107 cells/ 
ml) to which 10 μg of plasmid DNA was added. The mixture was 
incubated for 10 min on ice and electroporated in 0.4 cm cuvettes with 
one pulse of 0.4 kV/500 μΡ. The cells were then resuspended in 10 ml 
of DMEM/10% FCS and incubated for 24 h at 37°C. Transfected cells 
were collected after two weeks of neomycin selection (G418 1 mg/ml) 
in DMEM/10% FCS. 
The B16-PAGO ecotropic retro virus packaging cell line, kindly 
provided by R. Vile, was used as a source of the Moloney-based 
MMLV-PAGO replication defective viruses [15]. This retro virus en-
codes for the expression of the herpes simplex virus thymidine kinase 
(HSV-tk) gene, which confers to cell sensitivity to the toxic action of 
Gancyclovir (GCV). The packaging cell line was grown in DMEM/ 
10% FCS supplemented with neomycin (2.5 mg/ml). For the infection 
of fibroblast Balb/c-3T3 cells with PAGO virus, a total of 5X105 cells 
were incubated with 10 ml of supernatant of subconfluent B16-PAGO 
packaging cells (12 h of production of MMLV-PAGO virus; titer 105 
CFU/ml) for 5 h with Polybrene (4 μg/ml). After the infection, the 
cells were maintained for 24 h in growth medium and then incubated 
in the presence of GCV (10 μg/ml) for 2 weeks, changing the medium 
every 3 days. The antibody fragment D7aRT was detected in cell 
transfectants by Western analysis with the anti-myc-tag monoclonal 
antibody 9E10, as described [10]. 
2.3. Rescue of the neutralizing anti-RT antibody fragment DNA under 
viral selective pressure 
Balb/c-3T3 cells, transfected with a mixture of pScFvexp-D7txRT 
and pScFvexp-polyaRT DNA (ratio from 10~2 to 10-3), were in-
fected with PAGO virus as above. After two weeks of GCV selection, 
surviving cells were washed with PBS, and the level of the D7otRT 
and ScFv-polyaRT antibody fragment DNA in the cell population 
was monitored by using a semi-quantitative PCR analysis. Total cel-
lular DNA was prepared by a quick lysis method. Briefly, 105 cells 
were solubilized in 100 μΐ of lysis buffer (10 mM Tris-HCl pH 8.3, 50 
mM KC1, 2.5 mM MgCl2, 0.5% NP40, 0.5% Tween20, 50 μg/ml 
proteinase-K) and incubated for 1 h at 56°C. The samples were 
then boiled for 10 min to inactivate the proteinase-K. The D7aRT 
DNA was amplified by using a 5'-primer in the CHI region (human 
IgGl) and a 3'-primer in the ScFv-express vector myc-tag region. The 
polyaRT DNA was detected with a 5'-primer in the ScFv linker 
region and the same 3'-primer as above. To normalize for cellular 
DNA, mouse a2-tubulin DNA was amplified with 10-fold diluted 
samples. The PCR products were separated on 1.5% agarose gels, 
transferred onto Hybond-N+ membranes (Amersham), hybridized 
with 5'-end-labeled 32P-oligonucleotide probes and revealed by auto-
radiography. A subsaturating number of PCR cycles, as determined 
from preliminary experiments, was performed (22 cycles were rou-
tinely performed). 
negative cells and the cell population was challenged with 
the PAGO retrovirus, a Moloney-based replication defective 
retrovirus carrying the herpes virus thymidine kinase (HSV-
tk) as reporter gene [15]. The expression of HSV-tk converts 
the drug gancyclovir (GCV) into a toxic compound, thus 
leading to GCV-dependent cell death. After infection, the 
cell population was cultured with GCV and the levels of 
D7ocRT DNA and protein were monitored at different times 
of incubation with GCV. The results in Fig. 1A (Southern 
analysis of PCR products) clearly show that the DNA encod-
ing for D7aRT (top) is progressively enriched, as a function 
of incubation time with GCV, with respect to a housekeeping 
3. Results 
To rescue an anti-viral neutralizing antibody from an intra-
cellularly expressed polyclonal repertoire, the reverse tran-
scriptase (RT) was utilized as the target antigen and resistance 
to the killing action of a cytotoxic retrovirus as the selectable 
phenotype. We have recently described the isolation from a 
synthetic library of Fab fragments [12] of one antibody frag-
ment that neutralizes the RNA-dependent DNA-polymerase 
activity of HIV-1 RT, as well as that of RT from other retro-
virus [11]. A further characterization of the phage derived Fab 
fragment D7ocRT showed that the heavy chain alone 
(D7aRT) of this Fab fragment retains the ability to neutralize 
the activity of RTs of diverse origin [10]. The intracellular 
expression of the D7ocRT antibody fragment in the cytoplasm 
of mammalian cells leads to an efficient inhibition of viral 
retrotranscription by murine retro viruses [10]. 
As a prelude to intracellular library experiments, we per-
formed a model cell selection. To this aim, cells expressing the 
D7ocRT antibody fragment were diluted with an excess of 
Fig. 1. Rescue of D7aRT expressing cells under gancyclovir selec-
tive pressure. D7aRT expressing Balb/c3T3 cells were mixed at a ra-
tio of 10~2 with untransfected cells and infected with PAGO vi-
ruses. At different times after PAGO infection and GCV exposure, 
cells were collected and the levels of D7aRT protein and DNA as-
sayed. A: Southern analysis of PCR products. Total cellular DNA 
(104 cell equivalents/lane) was amplified by PCR with primers com-
plementary to the D7otRT and a2-tubulin genes and hybridized as 
described in Section 2. Cell samples derived before gancyclovir treat-
ment (lane 1), after 6 (lane 2), 12 (lane 3) and 20 days (lane 4) of 
GCV exposure were analyzed. B: Amount of radioactivity (Phos-
phorimager) in the hybridized D7aRT DNA bands, normalized to 
a2-tubulin. C: Western analysis of D7aRT protein during GCV se-
lection. 2.5X105 cells were collected before gancyclovir exposure 
(lane 1), after 6 (lane 2), or 12 days of GCV treatment (lane 3). 
The D7aRT protein was visualized with Mab 9E10. D7otRT control 
protein from baculovirus infected insect cells (lane 4). 
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Fig. 2. Selection of anti HIV-1 RT phage antibodies. Polyclonal 
anti-RT phage antibodies, selected from the Fab library [12] (shaded 
bars) or from the ScFv library [13] (filled bars), were assayed by 
ELISA for binding to HIV-1 RT in solid phase. The same polyclo-
nal phage antibodies were assayed for their ability to inhibit the 
RNA-dependent DNA-polymerase activity of HIV-1 RT. An equal 
number of phages derived from the unselected libraries was ana-
lyzed as controls (gray bars). 
gene (cx2-tubulin, bottom). Normalization to the ot2-tubulin 
gene yields the values shown in Fig. IB. Thus, cells harbour-
ing the D7aRT gene are progressively enriched in the popu-
lation. This enrichment of D7aRT DNA was further con-
firmed at the level of the corresponding protein, as shown 
by Western analysis of cell extracts taken at different times 
of GCV selection (Fig. 1C). These results demonstrate that 
cells expressing the D7ocRT antibody fragment, can be effi-
ciently rescued and expanded after two weeks of selection with 
GCV, using intracellular expression of the antibody fragment 
as the sole selectable marker. 
In order to explore the possibility of rescuing an anti-viral 
neutralizing antibody, from an intracellularly expressed poly-
clonal repertoire, we performed a new antibody selection, us-
ing recombinant HIV-1 RT [11] as a solid phase selector of a 
naive repertoire of human ScFv fragments [13]. This led, after 
three rounds of selection, to the isolation of a polyclonal 
population of phage-displayed ScFv fragments which reacted 
strongly with HIV-1 RT in ELISA. Single clones were grown, 
showing that approximately 10% of the individual phages 
were RT positive in ELISA. Fingerprinting analysis of the 
V-genes of ELISA-positive clones, amplified by PCR, showed 
a diversity in the order of 15 different ScFvs (data not shown). 
The polyclonal anti-RT phage population did not show any 
significant inhibition of RT activity in vitro (Fig. 2), under 
conditions in which the polyclonal phage population contain-
ing phage D7aRT (seventh cycle of selection, [11]) exerted a 
strong inhibition. 
We then sought to study the in vivo properties of the anti-
RT antibody fragments. To this aim, the bulk DNA encoding 
for the third round polyclonal ScFv-polyaRT fragments was 
subcloned into the ScFv-express vector [14], the same expres-
sion vector in which the neutralizing D7otRT antibody frag-
ment was previously cloned for expression in the cytoplasm of 
mammalian cells [10]. In order to perform a model selection 
from an 'intracellular library', the D7aRT DNA was mixed 
with increasing amounts of the polyclonal ScFv-polyaRT 
DNA. These DNA mixtures were transfected into Balb/c-
3T3 cells and, after two weeks in selective medium (neomy-
cin), cells were challenged with the PAGO retrovirus and cul-
tured with GCV. As shown in Fig. 3A, the number of surviv-
ing clones after GCV selection correlates closely with the 
input D7ccRT DNA in the transfection mixture, suggesting 
that cells expressing this neutralizing antibody fragment are 
being rescued, at the expense of cells expressing other anti-
body fragments. In order to verify whether the GCV resist-
ance correlates with the presence of the D7ocRT in the surviv-
ing cells, genomic DNA was extracted from the surviving cell 
population and the presence of genes encoding for polyocRT 
and for the D7rxRT fragments was assessed by semi-quanti-
tative PCR analysis with specific oligonucleotides that distin-
guish between the two antibody formats. The results are 
shown in Fig. 3B, demonstrating that while the gene encoding 
the neutralizing antibody fragment is enriched as the GCV 
selection proceeds, DNA encoding for the non-neutralizing 
ScFvs is being lost. It is noteworthy that the D7aRT DNA 
is enriched even when it was only present at a 10 - 3 dilution in 
the transfection mixture. 
These results confirm that only the cells expressing the neu-
tralizing antibody fragment can be efficiently rescued and ex-
panded after two weeks of selection with GCV, using intra-
cellular expression of the antibody fragment as the sole 
selection. Thus, this selection procedure can be used to rescue, 
in vivo, a neutralizing antibody fragment from a polyclonal 
background of non-neutralizing ones. 
4. Discussion 
These findings demonstrate that the intracellular expression 
in mammalian cells of a polyclonal repertoire of antibody 
fragments can be used to select antibodies on the basis of a 
given function. In fact, these experiments show that the ability 
of a neutralizing anti-reverse transcriptase antibody fragment 
Fig. 3. Rescue of the neutralizing anti-viral antibody fragment from 
an intracellular library. A: Survival of Balb/c-3T3 cells transfected 
with a mixture of D7oeRT and ScFv-polyaRT DNA at different ra-
tios (D7:ScFv =1:10, shaded bar; 1:100, empty bar; 1:1000, filled 
bar). Transfected cells were infected with PAGO virus, incubated 
for two weeks with GCV and the number of GCV resistant clones 
was determined. The values are the mean of two independent ex-
periments. B: Southern analysis of PCR products. Balb/c-3T3 cells, 
transfected with mixtures of D7aRT and ScFv-polyaRT DNA 
(lanes 1-2, D7:ScFv= 1:100; lanes 3^1, D7:ScFv= 1:1000), were 
challenged with PAGO and incubated with GCV. Before infection 
(lanes 1 and 3) and after 14 days of GCV treatment (lanes 2 and 
4), cellular DNA was amplified (104 cell equivalents/lane) with pri-
mers specific for D7aRT, SvFv-polyaRT and cellular a2-tubulin. 
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to confer cell resistance to a toxic retrovirus can be used in a 
selection scheme for its rescue against a background of non-
neutralizing ones, directed against the same protein. Intracel-
lular antibody expression has always been performed, so far, 
with genes derived from monoclonal antibodies [2,3] or with 
phage derived antibody fragments [10] of a well defined spe-
cificity. The use of phage derived antibody fragments has 
allowed us to provide a 'proof of principle' for the concept 
of intracellular libraries, whereby an affinity purified polyclo-
nal population of antibody fragments is intracellularly ex-
pressed. The design of a suitable selection scheme should al-
low the rescue of antibody specificities from the polyclonal 
repertoire. This strategy can be illustrated for the case of 
resistance to a cytotoxic virus, since this closely reflects the 
experimental design utilized for this work. A large phage dis-
play library of antibody fragments is challenged with an anti-
gen (Ag) involved in the viral life cycle and an affinity purified 
population of phages, enriched in anti-Ag specificities, and of 
greatly reduced diversity, is selected after few cycles. Bypass-
ing the in vitro characterization of individual antibodies in 
this polyclonal population, this small enriched repertoire is 
formatted for intracellular expression using appropriate vec-
tors [14], and is transfected as a pooled DNA in mammalian 
cells. Individual cells will express single specificities, or even a 
small subset of antibody specificities. By exposing the cell 
population to the selective pressure of a cytotoxic retrovirus, 
those antibody specificities interfering with the retroviral life 
cycle will confer a selective advantage to the cells harbouring 
them. These cells will therefore outgrow the culture. Finally, 
the neutralizing antibody fragments can be rescued from these 
cells and characterized. This scheme is rather broad, and need 
not be restricted to the phenotypic resistance to a cytotoxic 
virus. In fact, it should work, in principle, for all those cases 
were intracellular antibodies could provide a growth advan-
tage to cells expressing them. For instance, the selection of 
antibodies against apoptotic proteins, should be possible by 
this procedure. This approach is not limited to cytoplasmic 
expression, but can be applied to a number of different intra-
cellular compartments, provided a suitable selection scheme is 
available (NG and AC, unpublished data). It is clear however, 
as we are dealing with mammalian cells, that the size of the 
repertoire cannot be too large. Hence, the need of a preselec-
tion step, such as, for instance, an affinity purification on 
antigen column. We envisage that a repertoire size in the 
order of 103—104 is compatible with selection schemes in mam-
malian cells, not limiting the sensitivity of the assay to screen 
all possible candidates. For this reason, the experiments were 
performed with a dilution ratio of 10~3, and no attempt was 
made to improve on this, although it would have been possi-
ble, for instance by increasing the number of cells or the 
selection time. The polyclonal repertoire can also be restricted 
in alternative ways, such as for instance a small mutated li-
brary of a lead antibody fragment. This may allow selection 
for higher affinity or for improved intracellular performance 
to be achieved in vivo. Also, a number of procedures to enrich 
in specific binders of interest from a large library of antibodies 
could be used: for instance (i) subtraction methods for the 
enrichment of phage antibodies against proteins constituting 
a difference between two population of cells [16], or (ii) meth-
ods for panning of phage libraries on living cells [17]. The 
approach outlined in this paper can only be implemented by 
exploiting the phage technology, since only in this case it is 
possible to easily handle the recombinant version of a poly-
clonal antiserum. The design of a suitable selection scheme 
should allow to select antibodies against known or unknown 
epitopes. In conclusion, with antibodies derived from large 
display libraries, the intracellular targeting of polyclonal rep-
ertoires in mammalian cells is now feasible. 
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